U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt

Illumina

Market Cap: US$19.3b

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Exelixis

Market Cap: US$11.3b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

ACADIA Pharmaceuticals

Market Cap: US$3.8b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

ADMA Biologics

Market Cap: US$2.4b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Aurinia Pharmaceuticals

Market Cap: US$2.0b

A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.

Theravance Biopharma

Market Cap: US$862.0m

A biopharmaceutical company, develops and commercializes medicines in the United States.

CorMedix

Market Cap: US$595.3m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Abeona Therapeutics

Market Cap: US$308.9m

A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

Compugen

Market Cap: US$251.5m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Oramed Pharmaceuticals

Market Cap: US$156.9m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.